Activity profiling and structures of inhibitor-bound SARS-CoV-2-PLpro protease provides a framework for anti-COVID-19 drug design
W. Rut, Z. Lv, M. Zmudzinski, S. Patchett, D. Nayak, S. J. Snipas, F. El Oualid, M. Bekes, T. T. Huang, M. Drag, S. K. Olsen
This study profiles SARS-CoV-2-PLpro activity and determines inhibitor structures to guide anti-COVID-19 drug design.
bioRxiv · Apr 29, 2020 · PreprintBiochemistry